Skin condition

Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders

Retrieved on: 
Wednesday, March 27, 2024
ASLN, Disorder, Patient, SAN, Skin condition, Conference, Condition

ASLAN management will also be available for one-on-one meetings with investors on the day of the conference.

Key Points: 
  • ASLAN management will also be available for one-on-one meetings with investors on the day of the conference.
  • Please register for the event via this link or contact your representative at H.C. Wainright to schedule a meeting.
  • Institutional investors and industry participants are invited to register to listen to the presentation via this link .
  • A copy of the presentation will be posted to the Investor Relations section of ASLAN’s website after the event.

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Retrieved on: 
Tuesday, March 19, 2024
Skin condition, Disorder, Conference, Therapy, Condition

BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 28, 2024.

Key Points: 
  • BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 28, 2024.

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Retrieved on: 
Saturday, March 9, 2024
The Department, SAN, Immunodeficiency, Psoriasis, Doctor of Philosophy, Waldman, STAT1, IL22, MD, Mount Sinai Health System, Dermatitis, Atopic dermatitis, Biopsy, RNA-Seq, OASL, Rosacea, Laboratory, AAD, CXCL9, FA2H, Hospital, RNA, Immunology, IGA, Patient, Gene, PI3, Seborrhoeic dermatitis, Skin condition, Observational study, Skin, Research, Gene expression, American Academy, Vaccine

“We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.

Key Points: 
  • “We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.
  • These findings will help establish the groundwork for greater understanding of this very common condition.”
    “The pathophysiology of seborrheic dermatitis has been poorly understood.
  • In addition, the skin barrier disruption observed in seborrheic dermatitis has unique molecular underpinnings, primarily in the tight junction of the epithelial skin cells and lipid metabolism pathways.
  • These data demonstrate that seborrheic dermatitis is an immune disease with a uniquely polarized profile distinct from atopic dermatitis and plaque psoriasis.

Clinique Partners with Icahn School of Medicine at Mount Sinai to Establish the Mount Sinai-Clinique Healthy Skin Dermatology Center

Retrieved on: 
Friday, February 2, 2024
Other Health, Research, General Health, Pharmaceutical, Philanthropy, Hospitals, Cosmetics, Retail, Science, Other Philanthropy, Other Science, Health, MD, Hospital, Exercise, Atopic dermatitis, Informatics, Allergy, Clinique, Partnership, Ophthalmology, Knowledge, Alopecia areata, Diet, Artificial intelligence, Health system, Nursing, Mount Sinai Hospital, Patient, Laboratory, State, Community, Skin condition, Skin, Disease, Doctor of Philosophy, Mount, Therapy, Ageing, School, Physician, News, Mount Sinai Health System, Geriatrics

Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center.

Key Points: 
  • Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center.
  • Research conducted under the Mount Sinai-Clinique Healthy Skin Dermatology Center aims to uncover scientific findings to accelerate the creation of new topical and systemic treatments that help alleviate allergic skin conditions.
  • The priority is to bridge basic science with practical application in the clinic to improve people’s lives through healthy skin.
  • Dr. David Orentreich is Assistant Clinical Professor of Dermatology at Icahn Mount Sinai, and he and Dr. Catherine Orentreich are members of the Mount Sinai Dermatology Advisory Board.

AbelZeta Announces Formation of Scientific Advisory Board to Support Inflammatory and Immunological Diseases

Retrieved on: 
Wednesday, January 3, 2024
Arthritis, Quality of life, University, Canadian Aviation Regulations, Honorary, CD20, SLE, SAB, Society, Innovation, Cancer, Autoimmune disease, UCSF, Skin condition, Hospital for Special Surgery, B cell, Weill Cornell Medicine, Safety, Journal, Lupus nephritis, Human musculoskeletal system, Biomarker, Arthritis Foundation, Intramural sports, Patient, Hospital, Preventive healthcare, Division, Research, Jean, BCMA, Postgraduate education, Catholic League (German), Rheumatoid arthritis, Lupus Research Alliance, Conditional sentence, Bangladesh Technical Education Board, American College, Cell, CD19, Lee, Culture, Pharmaceutical industry

These four industry experts are distinguished scientific leaders with vast experience in the autoimmune disease field."

Key Points: 
  • These four industry experts are distinguished scientific leaders with vast experience in the autoimmune disease field."
  • Members of the SAB include:
    Peter Lipsky, M.D., served on the Board of Directors of the American College of Rheumatology.
  • She was President of the American College of Rheumatology, President of the Henry Kunkel Society, and Chair of the Scientific Advisory Board of the Lupus Research Alliance.
  • "AbelZeta is advancing promising new therapies for inflammatory and immunological diseases through innovative cell therapy platforms that provide custom-tailored treatment for each individual patient.

Bullous Pemphigoid Drug Pipeline Research Report 2023: Comprehensive Insights on 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, November 10, 2023
Pharmaceutical, Health, Other Health, NDA, Apoptosis, Interleukin 5, AstraZeneca, Neutrophil, Ageing, CH2, Skin, B cell, Clinical trial, Sanofi, Basophil, Macrophage, Patient, FDA, Mergers and acquisitions, Benralizumab, New Drug Application, Therapy, Atopic dermatitis, Regeneron Pharmaceuticals, Drug discovery, Eosinophil, Discovery, News, Dupilumab, Pharmaceutical industry, Vaccine, Health care, Skin condition, Bullous pemphigoid, Phase

The "Bullous Pemphigoid - Pipeline Insight, 2023" report offers comprehensive insights into the pipeline landscape for Bullous Pemphigoid, a skin disorder.

Key Points: 
  • The "Bullous Pemphigoid - Pipeline Insight, 2023" report offers comprehensive insights into the pipeline landscape for Bullous Pemphigoid, a skin disorder.
  • It covers information about more than 5 companies and over 5 pipeline drugs related to Bullous Pemphigoid.
  • Furthermore, the report offers a comprehensive overview of the current status and growth prospects within the Bullous Pemphigoid pipeline landscape.
  • Overall, this report offers a comprehensive and detailed analysis of the Bullous Pemphigoid pipeline landscape, providing valuable insights into the current status and future prospects of potential treatments for this skin disorder.

A New Hope for Epidermolysis Bullosa (“butterfly children”) Thanks to Novel CRISPR-Cas3 Platform

Retrieved on: 
Monday, October 30, 2023
Biotechnology, Health, Family, Consumer, Other Health, Pharmaceutical, Stem Cells, Other Science, Research, Children, Genetics, Health Technology, Science, Medical Supplies, Gene editing, Epidermolysis bullosa, Hope, CRISPR, Skin, Blister, Trauma, Multimedia, Quality of life, Skin condition, Entrepreneurship, EB, Friction, Pain, Patient, Vaccine

View the full release here: https://www.businesswire.com/news/home/20231030362422/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231030362422/en/
    Epidermolysis bullosa is a rare genetic skin disorder characterized by highly sensitive skin that blisters and erodes with minimal friction or trauma, such as rubbing or scratching.
  • EB affects approximately 20 out of every 1 million newborns in the United States where 25,000 to 50,000 young children are living with this debilitating condition.
  • The collaborative endeavor between Healiva and C4U will focus on the development of CRISPR-Cas3 based gene therapy for EB.
  • “By utilizing its proprietary CRISPR-Cas3 technology, a new generation of gene editing technology, C4U’s focus is to develop alternative and complete cures to genetic diseases.

BioMendics to Present on Epidermolysis Bullosa Simplex at the 7th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases

Retrieved on: 
Monday, October 30, 2023
Drug development, EBS, Chronic pain, Itch, Blister, Doctor of Philosophy, Autophagy, Epidermolysis bullosa simplex, Cell, Skin, Phase, Skin condition, Patient, Stanford University School of Medicine, Pharmaceutical industry, Dermatology

ROOTSTOWN, Ohio, Oct. 30, 2023 /PRNewswire/ -- BioMendics LLC, a pharmaceutical company developing new medicines to improve the lives of patients living with rare skin diseases, today announced its participation in the 7th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, taking place from October 31 - November 2 in Boston, Massachusetts.

Key Points: 
  • ROOTSTOWN, Ohio, Oct. 30, 2023 /PRNewswire/ -- BioMendics LLC, a pharmaceutical company developing new medicines to improve the lives of patients living with rare skin diseases, today announced its participation in the 7th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, taking place from October 31 - November 2 in Boston, Massachusetts.
  • Dr. Karen McGuire, CEO and Founder of BioMendics, will provide an update on the company's primary clinical program in epidermolysis bullosa simplex (EBS).
  • BioMendics completed their TAMES Phase I/IIa study with Stanford Medicine, Dermatology this summer in patients with severe EBS, and is planning on a Phase II study in 2024.
  • The completion of the Phase I/IIa study came on the heels of BioMendics receiving Orphan Drug Designation on May 1, 2023, for their proprietary molecule, BM-3103.

SINTX Technologies Awarded Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

Retrieved on: 
Wednesday, October 11, 2023
Silicon, DRS, Thomas Jefferson University, Acquisition, 3D, University of Pennsylvania School of Veterinary Medicine, Development, Human musculoskeletal system, Bacterial adhesion in aquatic system, Osseointegration, Veterinary medicine, Skin condition, University, Drexel University, Spine, SALT, Principal, FDA, PEEK, Arthritis, Phase, Infection, Bangladesh Technical Education Board, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, SBIR, Pharmaceutical industry, Medical device, Research

This represents the fourth NIH grant awarded to SINTX since the Phase I award for this project was received in September of 2021.

Key Points: 
  • This represents the fourth NIH grant awarded to SINTX since the Phase I award for this project was received in September of 2021.
  • Through the development of 3DP SN-PEEK spinal implants, SINTX aims to combine the familiarity and benefits of PEEK with the antibacterial and osteoconductive characteristics of silicon nitride.
  • These composite implants will be manufactured with modern, cost-effective 3D printing technologies.
  • “Our successful completion of Phase I aims has shown the feasibility and reliability of 3DP SN-PEEK spinal implants.

Stigmatisation a major impact of skin diseases across Europe, reveals JEADV study

Retrieved on: 
Sunday, October 8, 2023
European Academy of Allergy and Clinical Immunology, STD, Research, Advocacy, Prevalence, Burden, Skin, Atopic dermatitis, Stigmata, Psoriasis, Disease, Skin condition, Mental health, Journal of the European Academy of Dermatology and Venereology, Journal, Policy, Vertically transmitted infection, Hives, Life, Hair, Acne, Patient, Quality of life, Nursing, Dermatology, Venereology

Published today in the Journal of the European Academy of Dermatology and Venereology (JEADV), the diseases examined in the study included acne, atopic dermatitis, alopecia, psoriasis and sexually transmitted diseases (STDs).

Key Points: 
  • Published today in the Journal of the European Academy of Dermatology and Venereology (JEADV), the diseases examined in the study included acne, atopic dermatitis, alopecia, psoriasis and sexually transmitted diseases (STDs).
  • 88% patients with skin disease considered their disease to be embarrassing in their personal life, with 83% reporting the same in their working life.
  • The prevalence of skin diseases is likely to be significantly higher than this, as 40% of skin cancers and STD diagnoses remain unrecognised on first consultation.
  • Despite their high prevalence and psychological and physical impact, skin diseases receive limited policy, research and funding attention.